H
Hans J. Hammers
Researcher at University of Texas Southwestern Medical Center
Publications - 219
Citations - 20312
Hans J. Hammers is an academic researcher from University of Texas Southwestern Medical Center. The author has contributed to research in topics: Nivolumab & Renal cell carcinoma. The author has an hindex of 47, co-authored 192 publications receiving 15787 citations. Previous affiliations of Hans J. Hammers include Macquarie University & Harvard University.
Papers
More filters
Journal ArticleDOI
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Robert J. Motzer,Bernard Escudier,David F. McDermott,Saby George,Hans J. Hammers,Sandhya Srinivas,Scott S. Tykodi,Jeffrey A. Sosman,Giuseppe Procopio,Elizabeth R. Plimack,Daniel Castellano,Toni K. Choueiri,Howard Gurney,Frede Donskov,Petri Bono,John Wagstaff,Thomas Gauler,Takeshi Ueda,Yoshihiko Tomita,Fabio A.B. Schutz,Christian Kollmannsberger,James Larkin,Alain Ravaud,Jason S. Simon,Li-an Xu,Ian M. Waxman,Padmanee Sharma +26 more
TL;DR: Overall survival was longer and fewer grade 3 or 4 adverse events occurred with nivolumab than with everolimus among patients with previously treated advanced renal-cell carcinoma.
Journal ArticleDOI
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Robert J. Motzer,Nizar M. Tannir,David F. McDermott,Osvaldo Arén Frontera,Bohuslav Melichar,Toni K. Choueiri,Elizabeth R. Plimack,Philippe Barthélémy,Camillo Porta,Saby George,Thomas Powles,Frede Donskov,V. Neiman,V. Neiman,Christian Kollmannsberger,Pamela Salman,Howard Gurney,Robert E. Hawkins,Alain Ravaud,Marc-Oliver Grimm,Sergio Bracarda,Carlos H. Barrios,Yoshihiko Tomita,Daniel Castellano,Brian I. Rini,Allen C. Chen,Sabeen Mekan,M. Brent McHenry,Megan Wind-Rotolo,Justin Doan,Padmanee Sharma,Hans J. Hammers,Hans J. Hammers,Bernard Escudier +33 more
TL;DR: Overall survival and objective response rates were significantly higher with nivolumab plus ipilimumab than with sunitinib among intermediate‐ and poor‐risk patients with previously untreated advanced renal‐cell carcinoma.
Journal ArticleDOI
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
Toni K. Choueiri,Bernard Escudier,Thomas Powles,Paul N. Mainwaring,Brian I. Rini,Frede Donskov,Hans J. Hammers,Thomas E. Hutson,Jae-Lyun Lee,Katriina Peltola,Bruce J. Roth,Georg A. Bjarnason,Lajos Géczi,Bhumsuk Keam,Pablo Maroto,Daniel Y.C. Heng,Manuela Schmidinger,Philip W. Kantoff,Anne E. Borgman-Hagey,Colin Hessel,Christian Scheffold,Gisela Schwab,Nizar M. Tannir,Robert J. Motzer +23 more
TL;DR: Progression-free survival was longer with cabozantinib than with everolimus among patients with renal-cell carcinoma that had progressed after VEGFR-targeted therapy.
Journal ArticleDOI
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
Robert J. Motzer,Brian I. Rini,David F. McDermott,Bruce G. Redman,Timothy M. Kuzel,Michael R. Harrison,Ulka N. Vaishampayan,Harry A. Drabkin,Saby George,Theodore F. Logan,Kim Margolin,Elizabeth R. Plimack,Alexandre Lambert,Ian M. Waxman,Hans J. Hammers +14 more
TL;DR: Nivolumab demonstrated antitumor activity with a manageable safety profile across the three doses studied in mRCC, and no dose-response relationship was detected as measured by PFS.
Journal ArticleDOI
Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas.
Jing Zeng,Alfred P. See,Jillian Phallen,Christopher M. Jackson,Zineb Belcaid,Jacob Ruzevick,Nicholas M. Durham,Christian F. Meyer,Timothy J. Harris,Emilia Albesiano,Gustavo Pradilla,Eric C. Ford,John Wong,Hans J. Hammers,Dimitris Mathios,Betty Tyler,Henry Brem,Phuoc T. Tran,Drew M. Pardoll,Charles G. Drake,Michael Lim +20 more
TL;DR: The combination of PD-1 blockade and localized radiation therapy results in long-term survival in mice with orthotopic brain tumors, providing strong preclinical evidence to support combination trials in patients with GBM.